X

Drug Profile

Research programme: cobalamin-coated paclitaxel - Abeona Therapeutics

Latest Information Update: 24 May 2018

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Access Pharmaceuticals
Developer Abeona Therapeutics
Class Antineoplastics; Paclitaxels; Small molecules
Mechanism of Action Tubulin inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Discontinued Solid tumours

Most Recent Events

24 May 2018 Discontinued - Preclinical for Solid tumours in USA (IV)
10 Feb 2014 This programme is still in preclinical development in USA
10 Feb 2014 Research programme: cobalamin-coated paclitaxel - Access Pharmaceuticals is available for licensing as of 01 Mar 2013. http://www.accesspharma.com

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com